We’re honored to have been selected to present at this year’s Biotech Showcase.
CHARLOTTE, N.C. (PRWEB) December 17, 2014
OncoTab, Inc., a University of North Carolina at Charlotte (UNC Charlotte) spin-out company, announced today that it has been selected to present at the 7th Annual Biotech Showcase™. The invitation to participate in the prestigious biotechnology showcase comes on the heels of OncoTab’s rebranding and technology platform expansion.
OncoTab’s presentation will take place at 9 a.m. on Jan. 13, 2015. The Biotech Showcase takes place Jan. 12-14 at the Parc 55 Wyndham Hotel in San Francisco, Calif.
“We’re honored to have been selected to present at this year’s Biotech Showcase,” said OncoTab Chief Science Officer Pinku Mukherjee, PhD. “My team and I look forward to sharing the unique story of our trails and successes in developing new tools for diagnosing and treating cancer.”
Dr. Mukherjee, an Irwin Belk Endowed Professor for Cancer Research at UNC Charlotte, founded the company in 2011 to pursue diagnostic applications for breast cancer under the name CanDiag Inc. The newly renamed OncoTab’s expanded technology platform now includes tumor imaging and therapies.
“The Biotech Showcase gives us the opportunity to show industry leaders how far OncoTab has come,” said CEO Rahul Puri. “We dedicate all our time and energy to improving the quality and reducing cost of care and look forward to sharing our ideas for the future of cancer diagnosis and treatment.”
Produced by Demy-Colton Life Science Advisors and EBD Group, the Biotech Showcase provides public and private biotechnology companies with the opportunity to present and meet with potential investors. Organizers expect to attract more than 1,700 attendees including professional advisors, bankers, sector analysts, biopharmaceutical executives and private and public investors.
(This press release is not an offer to sell or the solicitation of an offer to buy shares or any other security in any jurisdiction.).
About OncoTab, Inc.
OncoTab (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNC Charlotte) spin-out that has licensed a patent-protected technology from the university with applications spanning the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up for a pivotal clinical study of its blood test and is pursuing additional diagnostic, imaging, and therapeutic product development and commercialization in the cancer space.